8-K
filed November 2, 2023, 7:59 PM ET
ticker PCRX
CIK 0001396814
earnings
confidence high
sentiment neutral
materiality 0.75
Pacira Q3 net income $10.9M, cuts FY EXPAREL guidance; CEO Stack to retire
Pacira BioSciences, Inc.
2023-Q3 EPS reported
$0.37
revenue$493,734,000
- Total revenues $163.9M, down ~2% YoY; EXPAREL sales $128.7M, down from $132.6M.
- GAAP net income $10.9M ($0.23/sh) vs net loss $0.7M in Q3 2022; adjusted EBITDA $52.9M.
- Lowers FY 2023 EXPAREL net product sales guidance to $535-540M from prior $550-560M.
- CEO Dave Stack will retire; remains until successor appointed, then consulting through Aug 2025.
- PDUFA action date for EXPAREL lower extremity nerve block on track for Nov 13, 2023.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
Pacira BioSciences, Inc. reported financial results for third quarter of 2023.
- Period
- third quarter of 2023
- Result
- reported results
Exact text from the filing
Total revenues were $163.9 million in the third quarter of 2023, versus $167.5 million reported for the third quarter of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
Pacira BioSciences, Inc. reported financial results for third quarter of 2023.
- Period
- third quarter of 2023
- Result
- reported results
Exact text from the filing
GAAP net income was $10.9 million, or $0.23 per share (basic and diluted) in the third quarter of 2023, compared to a net loss of $0.7 million, or $(0.02) per share (basic and diluted) in the third quarter of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
Pacira BioSciences, Inc. reported full-year 2023 results: revenue EXPAREL net product sales of $535 million to $540 million. Guidance lowered.
- Period
- full-year 2023
- Revenue
- EXPAREL net product sales of $535 million to $540 million
- Guidance
- lowered
- Result
- guidance update
Exact text from the filing
Pacira now expects full-year EXPAREL net product sales of $535 million to $540 million versus the company's previously guided range of $550 million to $560 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.